How long are you planning to stay here? antabuse reviews weight loss Fruquintinib is a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases and is currently in Phase II in China. Under the terms of the agreement, HMP will potentially receive up to $86.5 million, including upfront payments and development and regulatory approval milestones, plus tiered royalties. The deal only covers China at present.